hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06375733, orgStudyIdInfo id: GFH009X1202, briefTitle: A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Zhejiang Genfleet Therapeutics Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the safety and efficacy of GFH009 in combination with Zanubrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), conditionsModule conditions: Large B-cell Lymphoma, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 51, type: ESTIMATED, armsInterventionsModule interventions name: GFH009, interventions name: Zanubrutinib, interventions name: GFH009, interventions name: Zanubrutinib, outcomesModule primaryOutcomes measure: Phase Ib: adverse events(AEs), primaryOutcomes measure: Phase II: ORR, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Guangxi Medical University Cancer Hospital&Guangxi Cancer Institute, status: RECRUITING, city: Nanning, country: China, contacts name: Cen Hong, role: CONTACT, geoPoint lat: 22.81667, lon: 108.31667, locations facility: Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital, status: RECRUITING, city: Zhengzhou, country: China, contacts name: Keshu Zhou, role: CONTACT, geoPoint lat: 34.75778, lon: 113.64861, hasResults: False
protocolSection identificationModule nctId: NCT06375720, orgStudyIdInfo id: FujianUTCM-2, briefTitle: Efficacy of Different Doses of Tai Chi Chuan on Cognitive Function in Persons With Mild Cognitive Impairment, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-05, primaryCompletionDateStruct date: 2025-06-15, completionDateStruct date: 2025-12-15, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Lidian Chen, class: OTHER, collaborators name: Peking University Third Hospital, descriptionModule briefSummary: To determine the relationship between the effects of different frequencies and duration of Tai Chi Chuan in dose parameters to improve cognitive function in elderly persons with mild cognitive impairment., conditionsModule conditions: Mild Cognitive Impairment, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 350, type: ESTIMATED, armsInterventionsModule interventions name: Lower frequency, shorter period of Tai Chi Chuan, interventions name: Higher frequency, shorter period of Tai Chi Chuan, interventions name: Lower frequency, longer period of Tai Chi Chuan, interventions name: Higher frequency, longer period of Tai Chi Chuan, interventions name: Standard Health Education, outcomesModule primaryOutcomes measure: Montreal Cognitive Assessment, secondaryOutcomes measure: Montreal Cognitive Assessment, secondaryOutcomes measure: Wechsler Memory Scale, secondaryOutcomes measure: Digit Symbol Substitution Test, secondaryOutcomes measure: Trial Making Test part B, secondaryOutcomes measure: Stroop Color Word Test, secondaryOutcomes measure: Boston Naming Test, secondaryOutcomes measure: Rey-Osterrieth Complex Graphics Test, secondaryOutcomes measure: Rey Auditory Verbal Learning Test, otherOutcomes measure: The Pittsburgh Sleep Quality Index (PSQI), otherOutcomes measure: 12-Item Short Form Health Survey, otherOutcomes measure: Blood glucose metabolism index, otherOutcomes measure: Blood lipid metabolism index, otherOutcomes measure: functional Magnetic Resonance Imaging, otherOutcomes measure: Electroencephalogram, otherOutcomes measure: Heart rate variability, otherOutcomes measure: Gut microflora, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06375707, orgStudyIdInfo id: HERO-KC23, briefTitle: Efficacy and Safety of Ribociclib in Combination With NSAI Versus Physician's Choice of Chemotherapy Sequential Endocrine Therapy in HR+/HER2- Advanced Breast Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-09, primaryCompletionDateStruct date: 2025-11, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital with Nanjing Medical University, class: OTHER, collaborators name: Zhejiang Cancer Hospital, descriptionModule briefSummary: Evaluate the efficacy and safety of Ribociclib in combination with NSAI versus physician's choice of chemotherapy sequential endocrine therapy in HR+/HER2- advanced breast cancer., conditionsModule conditions: Advanced Breast Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 144, type: ESTIMATED, armsInterventionsModule interventions name: physician's choice of chemotherapy sequential Ribociclib combined with NSAI±OFS, interventions name: Ribociclib combined with NSAI±OFS, outcomesModule primaryOutcomes measure: Progression Free Survival, secondaryOutcomes measure: Progression Free Survival2, secondaryOutcomes measure: Time to treatment failure, secondaryOutcomes measure: Overall response rate (ORR), secondaryOutcomes measure: Overall survival(OS), secondaryOutcomes measure: Time To Response (TTR), secondaryOutcomes measure: Clinical benefit rate(CBR), secondaryOutcomes measure: Change from baseline in the global health status/QOL scale score by using FACT-B questionnaire, secondaryOutcomes measure: Frequency/severity of adverse events, lab abnormalities, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Jiangsu Provincial People's Hospital, status: RECRUITING, city: Nanjing, state: Jiangsu, zip: 210000, country: China, contacts name: Wei Li, Ph.D, role: CONTACT, phone: 025-68306360, email: real.lw@163.com, contacts name: Wei Li, Ph.D, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 32.06167, lon: 118.77778, hasResults: False
protocolSection identificationModule nctId: NCT06375655, orgStudyIdInfo id: STUDY20240085, briefTitle: Texting to Promote Breastfeeding (TOPS), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-31, primaryCompletionDateStruct date: 2025-07-31, completionDateStruct date: 2025-07-31, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: Lydia Furman, class: OTHER, descriptionModule briefSummary: The purpose of the study is to see if a program of text messages that support and promote breastfeeding for expecting and delivered African-American/Black women (called TEAM2BF), as compared to a national maternal health texting program (called Text4baby), can result in more women being able to breastfeed their infant. Because breastfeeding is healthy for mothers and babies, and because fewer African-American/Black women decide to breastfeed and continue breastfeeding than many other racial and ethnic groups, researchers like us are trying to figure out ways to be supportive to African-American/Black mothers who might be interested in breastfeeding. The investigators will enroll up to 80 mothers and their infants at UHCMC., conditionsModule conditions: Increased Breastfeeding, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Team2BF, interventions name: Text4baby, outcomesModule primaryOutcomes measure: Percentage of participants who do not opt out of receipt of text messages, primaryOutcomes measure: Percentage of participants who said texts were helpful as measured by questionnaire, primaryOutcomes measure: Percentage of participants who would refer a friend/family to the texting program, secondaryOutcomes measure: Percentage of participants who are exclusively breastfeeding at 2 months postpartum as measured by participant report/chart review, secondaryOutcomes measure: Percentage of participants who are exclusively breastfeeding as measured by participant report/chart review, secondaryOutcomes measure: Percentage of participants who are partially breastfeeding as measured by participant report/chart review, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ahuja Rainbow Center for Women and Children, city: Cleveland, state: Ohio, zip: 44103, country: United States, contacts name: Lydia Furman, MD, role: CONTACT, phone: 216-675-6691, email: lydia.furman@uhhospitals.org, geoPoint lat: 41.4995, lon: -81.69541, hasResults: False
protocolSection identificationModule nctId: NCT06375629, orgStudyIdInfo id: EDAP TMS, briefTitle: ES-HIFU, Prospective Data Collection of Patients Treated With Partial Gland HIFU Ablation for Prostate Cancer, acronym: ES-HIFU, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-04-20, primaryCompletionDateStruct date: 2027-04-20, completionDateStruct date: 2027-04-20, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: EDAP TMS S.A., class: INDUSTRY, descriptionModule briefSummary: The objective of this study is to evaluate the clinical effectiveness and safety of treatment of prostate cancer in patients who have received a focal HIFU treatment using the Focal One medical device., conditionsModule conditions: Prostate Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: FocalOne, outcomesModule primaryOutcomes measure: Evaluation of adverse events, primaryOutcomes measure: Evaluation of quality of life, primaryOutcomes measure: Evaluation of urinary incontinence, primaryOutcomes measure: Erectile function assessment, primaryOutcomes measure: Urinary Symptoms, eligibilityModule sex: MALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hospital Universitario Puerta del Mar, status: RECRUITING, city: Cadiz, zip: 21 11009, country: Spain, contacts name: Cristina Salvatierra Pérez, Doctor, role: CONTACT, phone: +34 956 00 21 00, email: cris_salvatierra86@hotmail.com, geoPoint lat: 36.52672, lon: -6.2891, locations facility: Hospital General Universitario Gregorio Marañón C/ Doctor Esquerdo, status: RECRUITING, city: Madrid, zip: 46 28007, country: Spain, contacts name: Carlos Hernández Fernández, Doctor, role: CONTACT, phone: +34 912 05 38 54, email: carlos.hernandez@salud.madrid.org, geoPoint lat: 40.4165, lon: -3.70256, locations facility: Hospital Universitario Central De Asturias, status: RECRUITING, city: Oviedo, zip: 33011, country: Spain, contacts name: Jorge Garcia Rodriguez, Doctor, role: CONTACT, phone: +34 985 10 80 00, email: garciajorge70@gmail.com, geoPoint lat: 43.36029, lon: -5.84476, locations facility: Hospital Universitario Marqués De Valdecilla, status: RECRUITING, city: Santander, zip: 39008, country: Spain, contacts name: Mario Dominguez Esteban, role: CONTACT, phone: +34 942 42 06 26, email: mariodominguezesteban@gmail.com, geoPoint lat: 43.46472, lon: -3.80444, locations facility: Hospital Consorcio General Universitario de Valencia, status: RECRUITING, city: Valencia, zip: 46014, country: Spain, contacts name: Emilio Mr López Alcina, Doctor, role: CONTACT, phone: +34 960 64 00 78, email: e.lopezalcina@gmail.com, geoPoint lat: 39.46975, lon: -0.37739, hasResults: False
protocolSection identificationModule nctId: NCT06375616, orgStudyIdInfo id: KY2024-023, briefTitle: Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2027-04, completionDateStruct date: 2027-04, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Shen Lei, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to compare the safety and efficacy of nafamostat mesylate (NM) and unfractionated heparin (UFH) in the process of renal replacement therapy (RRT) for patients suffering from sepsis associated acute kidney injury (SA-AKI). The main questions it aims to answer are:The impact of NM and UFH on platelet count in septic patients undergoing RRT treatment.The satisfaction with anticoagulation of NM and UFH in septic patients undergoing RRT treatment.The 28-day all-cause mortality rate of septic patients undergoing RRT treatment with NM and UFH.Researchers will use NM or UFH as anticoagulation during RRT in SA-AKI patients, assessing effects on platelet count, anticoagulation satisfaction, and mortality.Participants will receive NM or UFH as anticoagulation during RRT for a minimum of 7 days. Bleeding symptoms, platelet count and coagulation function will be monitored daily. Platelet changes during the 7-day treatment period and survival status at 28 days post-treatment will be recorded., conditionsModule conditions: Sepsis, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 156, type: ESTIMATED, armsInterventionsModule interventions name: Nafamostat Mesylate, interventions name: Unfractionated Heparin, outcomesModule primaryOutcomes measure: Platelet decline rate, secondaryOutcomes measure: Satisfaction of filter anticoagulation, otherOutcomes measure: All-cause mortality at 28 days, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Huashan Hospital, Fudan University, city: Shanghai, state: Shanghai, country: China, contacts name: Lei Shen, MD, role: CONTACT, phone: 86-021-52887920, email: sh_leisen@126.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06375603, orgStudyIdInfo id: SMARTALPHA-NERVEBLOX-1001, briefTitle: Nerve and Plane Block Data Collection Study for the Development of Artificial Intelligence-assisted Software, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-12-01, primaryCompletionDateStruct date: 2023-05-01, completionDateStruct date: 2023-05-01, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Smart Alfa Teknoloji San. ve Tic. A.S., class: INDUSTRY, collaborators name: Ankara University, descriptionModule briefSummary: The primary objective of this observational study is to acquire ultrasound images (raw data) from nerve and plane block regions to develop artificial intelligence-guided nerve block software (Nerveblox). The study aims to acquire raw ultrasound video from 200 volunteers' planned nerve and plane block regions. These participants will undergo ultrasound scans administered by expert clinicians proficient in these techniques in their clinical practice. The data collection devices utilized in this study are FDA-cleared general-purpose ultrasound devices., conditionsModule conditions: Ultrasound Imaging of Anatomical Structures, conditions: Nerve Block, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ACTUAL, armsInterventionsModule interventions name: Ultrasound scans, outcomesModule primaryOutcomes measure: Assessment of image quality, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ankara University School of Medicine, city: Ankara, zip: 06230, country: Turkey, geoPoint lat: 39.91987, lon: 32.85427, hasResults: False
protocolSection identificationModule nctId: NCT06375590, orgStudyIdInfo id: 2024-NavIIcusp, briefTitle: NavIIcusp: Bicuspid Aortic Valve Stenosis With Navitor Platform International Experience, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-05-01, completionDateStruct date: 2026-05-01, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Didier TCHETCHE, class: OTHER, collaborators name: Abbott, descriptionModule briefSummary: The aim of this prospective registry is to evaluate the clinical impact of the new Navitor prosthesis (Abbott, Minneapolis, MN, USA) in BAV and evaluate both the main sizing methods (the classical annular or the supra-annular with ICD measurement at 4 mm above the virtual basal ring)., conditionsModule conditions: Bicuspid Aortic Valve, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Transcatheter Aortic Valve Implantation, outcomesModule primaryOutcomes measure: 30-day device success (Rate), secondaryOutcomes measure: 1 year at least moderate bioprosthetic valve deterioration, secondaryOutcomes measure: 1 year severe patient-prosthesis mismatch, secondaryOutcomes measure: 30 days and 1 year all-cause and cardiovascular mortality, secondaryOutcomes measure: 30 days and 1 year stroke, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Clinique Pasteur, city: Toulouse, state: Occitanie, zip: 31076, country: France, contacts name: Didier Tchétché, MD, role: CONTACT, contacts name: Didier Tchétché, role: PRINCIPAL_INVESTIGATOR, contacts name: Chiara De Biase, MD, PhD, role: SUB_INVESTIGATOR, geoPoint lat: 43.60426, lon: 1.44367, hasResults: False
protocolSection identificationModule nctId: NCT06375564, orgStudyIdInfo id: XMYY-2020KY067-05, briefTitle: Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin αvβ3 Positive Expression, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-12-30, completionDateStruct date: 2026-12-30, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: The First Affiliated Hospital of Xiamen University, class: OTHER, descriptionModule briefSummary: This is an open-label, non-controlled, non-randomized study to assess the therapeutic efficacy of 177Lu-AB-3PRGD2 in patients with various solid tumors who will undergo radioligand therapy using 177Lu-AB-3PRGD., conditionsModule conditions: Refractory Solid Tumor, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: 177Lu-AB-3PRGD2 radioligand therapy, outcomesModule primaryOutcomes measure: Objective response rate (ORR), secondaryOutcomes measure: Incidence of treatment-related adverse events (safety and tolerability), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 90 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: The First Affiliated Hospital of Xiamen University, status: RECRUITING, city: Xiamen, state: Fujian, zip: 361003, country: China, contacts name: Haojun Chen, role: CONTACT, phone: +8618659285282, email: leochen0821@foxmail.com, contacts name: Hao Fu, MD, PhD, role: CONTACT, phone: +8615959230059, email: fuhaonuclear@163.com, contacts name: Haojun Chen, MD, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Hao Fu, MD, PhD, role: SUB_INVESTIGATOR, geoPoint lat: 24.47979, lon: 118.08187, hasResults: False
protocolSection identificationModule nctId: NCT06375538, orgStudyIdInfo id: B2022-527, briefTitle: Ultrasound Evaluations of Diaphragm and Intercostal Muscle to Predict the Failure of High-Flow Nasal Cannula Therapy, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-10-21, primaryCompletionDateStruct date: 2025-08-31, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-04-19, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Shanghai Zhongshan Hospital, class: OTHER, descriptionModule briefSummary: The study aims to predict the failure of High-flow Nasal Cannula oxygenation therapy by ultrasound evaluation of diaphragm and intercostal muscle contraction during the first 24 hours., conditionsModule conditions: High-flow Nasal Cannula, conditions: Ultrasound Evaluation, conditions: Diaphragm and Intercostal Muscle, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, outcomesModule primaryOutcomes measure: Ultrasound evaluation of diaphragm, primaryOutcomes measure: Ultrasound evaluation of intercostal muscle movement index, primaryOutcomes measure: The patient's condition deteriorated and required noninvasive or intubated invasive mechanical ventilation., secondaryOutcomes measure: ICU stay, secondaryOutcomes measure: Hospital stay, secondaryOutcomes measure: all cause mortality, secondaryOutcomes measure: Oxygen saturation, secondaryOutcomes measure: respiratory rate, secondaryOutcomes measure: oxygen concentration, secondaryOutcomes measure: flow velocity of HFNC, secondaryOutcomes measure: VT, secondaryOutcomes measure: duration on HFNC, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Zhongshan Hospital, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200032, country: China, contacts name: Wei Wu, role: CONTACT, phone: 13817976707, email: wu.wei1@zs-hospital.sh.cn, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False